Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Protagonist Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Protagonist Announces Positive Results for Icotrokinra in Phase 3 Plaque Psoriasis
Details : JNJ-2113 (icotrokinra) is a first and only targeted oral peptide that is designed to selectively block the IL-23R. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Brand Name : JNJ-2113
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 18, 2024
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Protagonist Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?